Effects of Omega-3 Fatty Acids on Platelets in Patients With Coronary Artery Disease With Hypertriglyceridemia
Status:
Unknown status
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
Omacor®/Lovaza® is an effective, and very safe mix of PO-3A, and the drug is currently
approved by the Federal authorities for the drug management of post-infarction patients with
high blood triglycerides. Given the growing length of CAD progression, it is pertinent that
many more patients will yield extra benefit from Lovaza® on top of aggressive antiplatelet
regimens and statin due to severity of their vascular disease. Therefore, mild antiplatelet
properties of PO-3A will be a highly desirable and attractive commodity of this medication.
The investigators believe that Omacor®/Lovaza® is ideally positioned for the chronic
management of CAD as a safe, efficient, and "gentle" agent with no harmful interactions with
statins or aspirin.
The investigators hypothesize that addition of Omacor may add mild antiplatelet protection
for CAD patients.
The study objectives are:
- To assess the ex vivo effects of Omacor® on platelet function in patients with coronary
artery disease (CAD).
- To compare ex vivo platelet-related effects after 7 and 14 days of therapy with Omacor
and statin combination versus statin alone in patients with chronic stable coronary
heart disease.
- To establish the relation of changes in platelet activity (if any) with the lipid
profile to prove an additional benefit of Omacor® on top of statin and aspirin.